Liminatus Pharma, Inc.
LIMN
$5.54
-$0.61-9.92%
NASDAQ
| 03/31/2024 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -94.01% | ||||
| Total Receivables | 74.07% | ||||
| Inventory | -- | ||||
| Prepaid Expenses | 81.82% | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | 4.29% | ||||
| Total Current Assets | 15.44% | ||||
|
|
|||||
| Total Current Assets | 15.44% | ||||
| Net Property, Plant & Equipment | 0.00% | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -- | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | -- | ||||
| Total Assets | 15.43% | ||||
|
|
|||||
| Total Accounts Payable | 0.64% | ||||
| Total Accrued Expenses | 103.96% | ||||
| Short-term Debt | 7.48% | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | -- | ||||
| Total Finance Division Other Current Liabilities | 1.03% | ||||
| Total Other Current Liabilities | 1.03% | ||||
| Total Current Liabilities | 11.64% | ||||
|
|
|||||
| Total Current Liabilities | 11.64% | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | 7.48% | ||||
| Capital Leases | -- | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -- | ||||
| Total Liabilities | 11.64% | ||||
|
|
|||||
| Common Stock & APIC | 0.00% | ||||
| Retained Earnings | -6.98% | ||||
| Treasury Stock & Other | -- | ||||
| Total Common Equity | -11.11% | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | -- | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | -- | ||||
|
|
|||||
| Total Common Equity | -11.11% | ||||
| Total Preferred Equity | -- | ||||
| Total Minority Interest | -- | ||||
| Total Equity | -11.11% | ||||
|
|
|||||